• Michelangelo Sartori and Benilde Cosmi.
• Department of Angiology and Blood Coagulation, S. Orsola-Malpighi University Hospital, Pad. 2, via Albertoni, 15, 40138, Bologna, Italy. michelangelo.sartori@aosp.bo.it.
• J. Thromb. Thrombolysis. 2018 Apr 1; 45 (3): 345-352.

AbstractDirect oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexanet alfa, is being developed that binds FXa direct inhibitors in their active site, thus reversing their anticoagulant effect. The purpose of this article is to review the design, development and clinical trials of andexanet alfa. Andexanet alfa was shown to reverse FXa inhibitors anticoagulant activity both in thrombosis animal models, healthy volunteers and patients with acute major bleeding. Andexanet alfa has been studied in double-blind, placebo-controlled phase II and III studies. A preliminary report of the phase III study showed that an effective hemostasis was obtained after andexanet alfa infusion in the majority of the patients with acute major bleeding associated with FXa inhibitors. Additional studies are ongoing and andexanet alfa is expected to be launched in the market in the near future.

17 keywords...

hide…